Alnylam Reports Patient Death in Fitusiran Clinical Study
Alnylam Pharmaceuticals, Inc. has reported on the death of a hemophilia A patient who had been participating in a Phase 2 open label extension study for the company’s investigational therapy fitusiran which is being developed for patients with hemophilia A and B, both...Newsletter Sign Up
Learn more about the bleeding disorders community!